IGC Pharma Reports Canadian Patent Grant for IGC-AD1 as CALMA Trial Enters Final Dosing
IGC Pharma said Canadian Patent No. 3,095,729 has been granted for IGC-AD1, an investigational oral therapy being evaluated for agitation in Alzheimer’s dementia.
IGC Pharma, Inc. (NYSE American:IGC) said a Canadian patent has been granted for IGC-AD1, its investigational oral therapy for agitation in Alzheimer’s dementia. The company also reported that its CALMA Phase 2 study has completed enrollment and is in its final dosing period.
The Canadian Intellectual Property Office granted Canadian Patent No. 3,095,729, titled “Method and Composition for Treating CNS Disorders”. The patent covers the composition of IGC-AD1.
IGC Pharma said issued patents covering IGC-AD1 are now in the United States, Canada and Mexico. The cited patents are U.S. Patent No. 12,465,589, Canadian Patent No. 3,095,729 and Mexican Patent No. 409,414.
Overall, the company said IGC-AD1 is covered by 5 granted patents, with 10 more applications pending worldwide. IGC Pharma also identified risks that issued patents could be challenged, narrowed or circumvented.
IGC-AD1 is being assessed in CALMA, a randomized, double-blind, placebo-controlled Phase 2 trial focused on agitation in Alzheimer’s dementia. IGC Pharma said enrollment was completed in September 2026 and that the study is now in its final dosing period.
The company said topline results will follow database lock and unblinding. It also stated that there can be no assurance regarding the timing or outcome of the CALMA trial. The company cited possible delays involving trial completion, data collection, verification and analysis, as well as uncertainty over IGC-AD1’s safety and efficacy and whether the trial will meet its endpoints.
IGC Pharma describes IGC-AD1 as an investigational oral liquid designed to address several biological mechanisms linked to agitation, including neuroinflammation, CB1 receptor signaling and neurotransmitter regulation.
IGC-AD1 has not been approved by the U.S. Food and Drug Administration or any other regulatory authority. The company said additional clinical trials and regulatory review may be required, and also cited financing needs among the risks associated with development.
IGC Pharma is a clinical-stage biotechnology company working on Alzheimer’s disease therapeutics and artificial intelligence-enabled healthcare technologies. Its stated pipeline includes TGR-63, which targets amyloid plaques, along with early-stage programs focused on neurodegeneration, tau proteins and metabolic dysfunctions.
CEO Ram Mukunda said patent protection is central to the company’s strategy for IGC-AD1. He said IGC Pharma aims to combine clinical evidence with patent protection to support long-term commercial value and help attract major pharmaceutical partners if the therapy is approved. The company stated that there can be no assurance regarding commercialization or any pharmaceutical partnership.
IGC Pharma announced that the Canadian Intellectual Property Office granted Canadian Patent No. 3,095,729, “Method and Composition for Treating CNS Disorders”, covering the composition of IGC-AD1. IGC-AD1 is an investigational oral therapy for agitation in Alzheimer’s disease.
IGC-AD1 is protected by issued patents in the United States, Canada and Mexico. The cited patents are U.S. Patent No. 12,465,589, Canadian Patent No. 3,095,729 and Mexican Patent No. 409,414.
IGC Pharma said IGC-AD1 is protected by 5 granted patents, with 10 more applications pending worldwide. The company said strong patent protection is central to its strategy for IGC-AD1.
IGC-AD1 is being developed as an investigational oral therapy for agitation in Alzheimer’s dementia. IGC Pharma described agitation as one of the hardest parts of the disease for families and caregivers to manage.
IGC Pharma said CALMA completed enrollment in September 2026 and is in its final dosing period. The trial is a randomised, double-blind, placebo-controlled Phase 2 study evaluating IGC-AD1 for agitation in Alzheimer’s dementia.
IGC Pharma said topline results will follow database lock and unblinding. The company also stated that there can be no assurance regarding the timing or outcome of the CALMA trial.
IGC Pharma said IGC-AD1 is an investigational oral liquid designed to address multiple biological mechanisms implicated in agitation, including neuroinflammation, CB1 receptor signalling and neurotransmitter regulation.
CEO Ram Mukunda said strong patent protection is central to IGC Pharma’s strategy for IGC-AD1 and that the patents strengthen the company’s intellectual property portfolio. He said the company’s vision is to combine clinical evidence with patent protection to support long-term commercial value and help attract major pharmaceutical partners, if approved.
IGC Pharma said its pipeline includes TGR-63, which targets amyloid plaques, as well as early-stage programmes focused on neurodegeneration, tau proteins and metabolic dysfunctions. The company said it uses artificial intelligence to accelerate drug discovery, optimise clinical trials and enhance patient targeting.
IGC Pharma is a clinical-stage biotechnology company advancing Alzheimer’s disease therapeutics and artificial intelligence-enabled healthcare technologies. The company said its lead asset, IGC-AD1, is a cannabinoid-based therapy in a Phase 2 trial for agitation in Alzheimer’s dementia.
IGC Pharma’s shares trade on NYSE American under the ticker symbol IGC.
IGC Pharma identified potential delays in trial completion, data collection, verification and analysis, as well as uncertainty over the safety and efficacy of IGC-AD1 and whether CALMA will meet its endpoints. The company also cited possible additional clinical trials and regulatory review, financing needs, and the risk that issued patents may be challenged, narrowed or circumvented; IGC-AD1 has not been approved by the U.S. Food and Drug Administration or any other regulatory authority.